Compugen (CGEN) Return on Capital Employed (2009 - 2026)
Compugen's (CGEN) quarterly Return on Capital Employed came in at 24.73% in Q1 2026, up 4064.0% year-on-year from 0.59% in Q1 2025, and down 17.39% quarter-over-quarter from 29.94% in Q4 2025.
Compugen (CGEN) Return on Capital Employed (2009 - 2026) Analysis & Trends
Compugen has disclosed Return on Capital Employed across 18 years of filings, most recently posting 24.73% for Q1 2026.
- Return on Capital Employed for Q1 2026 came in at 24.73%, up 4064.0% year-over-year; the trailing twelve-month figure through Mar 2026 was 24.73% (up 4064.0% YoY), and the FY2025 annual result was 27.67%, up 4286.0% from the prior year.
- Return on Capital Employed came in at 24.73% for Q1 2026 at Compugen, down from 29.94% in the prior quarter.
- In the past five years, Return on Capital Employed ranged from a high of 29.94% in Q4 2025 to a low of 55.69% in Q3 2023.
- The 5-year median for Return on Capital Employed is 15.03% (2024), against an average of 9.98%.
- Across the five-year window, Return on Capital Employed slumped 5532 bps in 2023 and surged 6756 bps in 2024, its largest moves.
- Compugen's Return on Capital Employed stood at 3.67% in 2022, then tumbled by 619 bps to 19.05% in 2023, then rose by 21 bps to 15.03% in 2024, then jumped by 299 bps to 29.94% in 2025, then dropped by 17 bps to 24.73% in 2026.
- The last three Return on Capital Employed figures came in at 24.73% (Q1 2026), 29.94% (Q4 2025), and 39.32% (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | ROCE (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | 450.31% |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | 51.73% |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | -107.40% |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | 21.10% |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | -50.43% |
| 10 | Compugen | 189.59 Mn | 97.83 Mn | 352,000.00 | 24.73% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 24.73% |
| Dec 31, 2025 | 29.94% |
| Sep 30, 2025 | -39.32% |
| Jun 30, 2025 | -21.91% |
| Mar 31, 2025 | -15.91% |
| Dec 31, 2024 | -15.03% |
| Sep 30, 2024 | 11.87% |
| Jun 30, 2024 | -5.22% |
| Mar 31, 2024 | -15.75% |
| Dec 31, 2023 | -19.05% |
| Sep 30, 2023 | -55.69% |
| Jun 30, 2023 | -51.64% |
| Mar 31, 2023 | 29.23% |
| Dec 31, 2022 | 3.67% |
| Sep 30, 2022 | -2.37% |
| Jun 30, 2022 | 3.68% |
| Mar 31, 2022 | -30.96% |
| Dec 31, 2021 | -31.81% |
| Sep 30, 2021 | -32.94% |
| Jun 30, 2021 | -31.96% |